Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SEMAFOLLOW questionnaire.
- Who it may be relevant to
- Registry conditions: Obesity & Overweight. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France
Overview
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Interventions
- Other SEMAFOLLOW questionnaire
If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes
Primary outcome measures
- Describe weight changes during the follow-up period according to patient characteristics. [Time frame: Baseline]
Secondary outcome measures (3)
- Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors. [Time frame: Baseline]
- Compare the profiles of responders and non-responders [Time frame: Baseline]
- Describe weight change according to different subpopulations. [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
- No objection to the use of their data
- Patients able to complete an online questionnaire (via the internet)
Exclusion criteria
- Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Nantes university hospital — Nantes
Identifiers
NCT: NCT07423481 · RC25_0446 · 2026-A00299-42